https://www.selleckchem.com/
Valproate is a known teratogen. In April 2018, the Medicines and Healthcare products Regulatory Agency (MHRA) restricted its use in women and banned use in pregnancy, except for epilepsy with no other effective treatment. To date, there is limited information on valproate prescribing within primary care. To characterise valproate prescribing to women of childbearing age, recorded advice or GP prescribed contraception, and recorded pregnancies. A cross-sectional study of patients from all 141 general practices across three clinical commissioning groups (CCGs
Like
Comment
Share
